Skip to content

Comparing the Safety and Effectiveness of Tunnel PICC Guided by EDUG and Conventional PICC

Comparing the Safety and Efficacy of EDUG-guided Tunnel PICC With Conventional PICC in Immunocompromised Patients: a Multicenter, Prospective, Randomized Controlled Clinical Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05621473
Acronym
PICC
Enrollment
420
Registered
2022-11-18
Start date
2022-12-01
Completion date
2023-12-31
Last updated
2022-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the Incidence of PICC-related Complications

Brief summary

This study was designed as a prospective, multicenter, randomized controlled study, with the incidence of postoperative complications as the main observation end point. It was a superiority design.The purpose of this study was to compare the incidence of complications associated with EDUG-guided subcutaneous tunneling and conventional puncture after peripheral vein placement of PICCs

Interventions

DEVICEPICC

Tunnel PICC puncture technology is a perfect combination of ultrasound-guided puncture, ECG lead technology, PICC and subcutaneous tunnel. The valve conduction PICC is equipped with an integrated ECG lead Doppler ultrasound machine. Before the catheter is placed, in the yellow area, in the ultrasound mode, evaluate the blood vessel condition, measure the blood flow velocity, and correctly select the puncture site. When the catheter is pushed close to the superior vena cava, the electrocardiograph mode is switched to complete the precise positioning of the catheter according to the principle of ECG positioning technology. A subcutaneous tunnel was prepared in the green area, and the PICC at the puncture site in the yellow area was introduced to the green area and carefully bandaged. Whole-process integrated operation, simple and efficient operation.

Sponsors

Wuhan University
CollaboratorOTHER
Enshi Clinical College of Wuhan University
CollaboratorUNKNOWN
Jingzhou Central Hospital
CollaboratorOTHER
The Central Hospital of Huanggang
CollaboratorOTHER
Hubei Cancer Hospital
CollaboratorOTHER
Yichang Central People's Hospital
CollaboratorOTHER
Sinopharm Gezhouba Group Central Hospital
CollaboratorUNKNOWN
Central Hospital of Xiaogan
CollaboratorOTHER
Xiaogan First People's Hospital
CollaboratorUNKNOWN
Wuhan Central Hospital
CollaboratorOTHER
Xiangyang Central Hospital
CollaboratorOTHER
Xiangyang No.1 People's Hospital
CollaboratorOTHER
Shandong Branden Med.Device Co.,Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years old; * Immunocompromised patients, including: ① Patients with congenital T cell/B cell deficiency or macrophage disorder; ② Patients with solid malignant tumors or hematological malignancies; ③ Patients with AIDS; ④ Patients undergoing splenectomy or solid organ transplantation; ⑤ Patients with rheumatic diseases and treated with immunomodulatory drugs; * Follow the doctor's advice to perform PICC catheterization for the first time; * No serious cardiovascular disease, such as atrial fibrillation, pulmonary heart disease, severe conduction block, etc., before catheter placement; * Patients who have not participated in other clinical studies; * Patients who voluntarily participate in the clinical study and can cooperate with the clinical follow-up.

Exclusion criteria

* Known allergy to catheter material; * History of infection, injury or radiation therapy at the puncture site; * There is a history of venous thrombosis or surgical operation at the puncture site; * Severe abnormal coagulation function; * Superior vena cava compression syndrome; * Radical mastectomy for breast cancer or axillary lymph node dissection on the operative side of the limb; * Pacemaker and arteriovenous fistula ipsilateral limb.

Design outcomes

Primary

MeasureTime frameDescription
rate of PICC-related complications6 months after operationObserve and record the incidence of catheter-related complications during catheter placement, such as bleeding, subcutaneous congestion, lymphatic exudation, phlebitis (bacterial phlebitis, mechanical phlebitis, thrombophlebitis), infection (local infection, tunneling) Infection, catheter-related bloodstream infection), thrombosis (symptomatic thrombosis, asymptomatic thrombosis), catheter ectopic, medical adhesive-related skin injury, catheter injury and blockage, etc.

Secondary

MeasureTime frameDescription
rate of unplanned extubationthrough study completion, an average of 4monthsthe incidence of unplanned extubation
success rate of one-time catheter placementone hour
time of catheter indwellingIntraoperative (Time from successful catheter insertion to extubation)Time from successful catheter insertion to extubation
score of operation convenienceone hour
score of patient comfortone hour
operation timeone hour

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026